Interferon-Alpha Shows Promise in Reducing Myelofibrosis Risk and Mortality in Polycythemia Vera Patients
Interferon-alpha (IFN) has been shown to delay and potentially prevent post-polycythemia vera (PV) myelofibrosis (MF) and improve survival rates among PV patients, according to findings from a single-center, retrospective study presented at the 2020 ASH Annual Meeting and Exposition. The study, led by Ghaith Abu-Zeinah, MD, highlighted that IFN reduces the risk of myelofibrosis by 9% per year and decreases overall mortality by 6% per year, independent of age, sex, thrombosis history, cardiovascular risk factors, or other treatments.
Key Findings:
- Myelofibrosis Risk Reduction: IFN treatment was associated with a significant reduction in the risk of developing myelofibrosis.
- Survival Improvement: Patients treated with IFN showed improved overall survival, especially in high-risk PV cases.
- Bone Marrow Response: In some patients, IFN treatment led to complete bone marrow responses, with bone marrow fibrosis being reversed.
The study analyzed data from 470 patients diagnosed with PV between 1966 and 2019, focusing on those treated with IFN, hydroxyurea (HU), or phlebotomy only. High-risk PV patients treated with IFN had a 20-year overall survival probability of 66%, compared to 40% in the HU group and 14% in the phlebotomy-only group. For low-risk patients, the myelofibrosis-free survival rate was significantly higher in the IFN group (84%) compared to the HU (65%) and phlebotomy-only (55%) groups.
Clinical Implications:
- The findings suggest that IFN could be considered as a long-term management strategy for low-risk PV patients and preferred over HU for high-risk patients, based on the study's data and ongoing clinical trials.
- Current guidelines from the National Comprehensive Cancer Network and European LeukemiaNet recommend phlebotomy-only as initial treatment for low-risk patients and either HU or IFN for high-risk patients. However, this study advocates for a reconsideration of IFN's role in PV treatment strategies.
This research underscores the potential of IFN as a disease-modifying therapy in PV, addressing the unmet need for life-prolonging therapies in this patient population.